ALT 0 3 0 3 B-clinical_variable
( 4 5 4 5 I-clinical_variable
SGPT 5 9 5 9 I-clinical_variable
) 9 10 9 10 I-clinical_variable
≤ 11 12 11 12 O
3 13 14 13 14 B-upper_bound
X 15 16 15 16 I-upper_bound
institutional 17 30 17 30 I-upper_bound
ULN 31 34 31 34 I-upper_bound

AST 0 3 35 38 B-clinical_variable
( 4 5 39 40 I-clinical_variable
SGOT 5 9 40 44 I-clinical_variable
) 9 10 44 45 I-clinical_variable
≤ 11 12 46 47 O
3 13 14 48 49 B-upper_bound
X 15 16 50 51 I-upper_bound
institutional 17 30 52 65 I-upper_bound
ULN 31 34 66 69 I-upper_bound

Absolute 0 8 70 78 B-clinical_variable
neutrophil 9 19 79 89 I-clinical_variable
count 20 25 90 95 I-clinical_variable
≥ 26 27 96 97 O
1,500 28 33 98 103 B-lower_bound
/ 33 34 103 104 I-lower_bound
mcL 34 37 104 107 I-lower_bound

Active 0 6 108 114 B-chronic_disease
infection 7 16 115 124 I-chronic_disease
with 17 21 125 129 I-chronic_disease
hepatitis 22 31 130 139 I-chronic_disease
B 32 33 140 141 I-chronic_disease
or 34 36 142 144 I-chronic_disease
hepatitis 37 46 145 154 I-chronic_disease
C 47 48 155 156 I-chronic_disease
virus 49 54 157 162 I-chronic_disease

Arterial 0 8 163 171 B-cancer
ischemic 9 17 172 180 I-cancer
event 18 23 181 186 I-cancer
( 24 25 187 188 O
e.g. 25 29 188 192 O
, 29 30 192 193 O
unstable 31 39 194 202 B-chronic_disease
angina 40 46 203 209 I-chronic_disease
, 46 47 209 210 O
myocardial 48 58 211 221 B-chronic_disease
infarction 59 69 222 232 I-chronic_disease
, 69 70 232 233 O
stroke 71 77 234 240 B-chronic_disease
) 77 78 240 241 O
within 79 85 242 248 O
6 86 87 249 250 B-upper_bound
months 88 94 251 257 I-upper_bound
of 95 97 258 260 O
study 98 103 261 266 O
entry 104 109 267 272 O

Electrocardiogram 0 17 273 290 O
without 18 25 291 298 O
evidence 26 34 299 307 O
of 35 37 308 310 O
acute 38 43 311 316 B-chronic_disease
cardiac 44 51 317 324 I-chronic_disease
ischemia 52 60 325 333 I-chronic_disease
within 61 67 334 340 O
14 68 70 341 343 B-upper_bound
days 71 75 344 348 I-upper_bound
prior 76 81 349 354 I-upper_bound
study 82 87 355 360 O
registration 88 100 361 373 O

Evidence 0 8 374 382 O
of 9 11 383 385 O
significant 12 23 386 397 O
medical 24 31 398 405 B-chronic_disease
illness 32 39 406 413 I-chronic_disease
, 39 40 413 414 O
abnormal 41 49 415 423 O
laboratory 50 60 424 434 O
finding 61 68 435 442 O
, 68 69 442 443 O
or 70 72 444 446 O
psychiatric 73 84 447 458 B-chronic_disease
illness 85 92 459 466 I-chronic_disease
/ 92 93 466 467 I-chronic_disease
social 93 99 467 473 I-chronic_disease
situations 100 110 474 484 I-chronic_disease
that 111 115 485 489 O
would 116 121 490 495 O
, 121 122 495 496 O
in 123 125 497 499 O
the 126 129 500 503 O
Investigator 130 142 504 516 O
's 142 144 516 518 O
judgment 145 153 519 527 O
, 153 154 527 528 O
make 155 159 529 533 O
the 160 163 534 537 O
patient 164 171 538 545 O
inappropriate 172 185 546 559 O
for 186 189 560 563 O
this 190 194 564 568 O
study 195 200 569 574 O

HIV 0 3 575 578 B-chronic_disease
- 3 4 578 579 O
positive 4 12 579 587 O
subjects 13 21 588 596 O
on 22 24 597 599 O
combination 25 36 600 611 B-treatment
antiretroviral 37 51 612 626 I-treatment
therapy 52 59 627 634 I-treatment
are 60 63 635 638 O
ineligible 64 74 639 649 O
because 75 82 650 657 O
of 83 85 658 660 O
the 86 89 661 664 O
potential 90 99 665 674 O
for 100 103 675 678 O
pharmacokinetic 104 119 679 694 O
interactions 120 132 695 707 O
with 133 137 708 712 O
capecitabine 138 150 713 725 B-treatment
and/or 151 157 726 732 O
bevacizumab 158 169 733 744 B-treatment

History 0 7 745 752 O
of 8 10 753 755 O
allergic 11 19 756 764 O
reactions 20 29 765 774 O
attributed 30 40 775 785 O
to 41 43 786 788 O
compounds 44 53 789 798 O
of 54 56 799 801 O
similar 57 64 802 809 O
chemical 65 73 810 818 O
or 74 76 819 821 O
biologic 77 85 822 830 O
composition 86 97 831 842 O
to 98 100 843 845 O
capecitabine 101 113 846 858 B-allergy_name
or 114 116 859 861 O
bevacizumab 117 128 862 873 B-allergy_name

In 0 2 874 876 O
- 2 3 876 877 O
range 3 8 877 882 O
international 9 22 883 896 B-clinical_variable
normalized 23 33 897 907 I-clinical_variable
ratio 34 39 908 913 I-clinical_variable
( 40 41 914 915 O
between 41 48 915 922 O
2 49 50 923 924 B-lower_bound
and 51 54 925 928 O
3 55 56 929 930 B-upper_bound
) 56 57 930 931 O
on 58 60 932 934 O
a 61 62 935 936 O
stable 63 69 937 943 O
dose 70 74 944 948 O
of 75 77 949 951 O
oral 78 82 952 956 B-treatment
anticoagulant 83 96 957 970 I-treatment
or 97 99 971 973 O
on 100 102 974 976 O
a 103 104 977 978 O
stable 105 111 979 985 O
dose 112 116 986 990 O
of 117 119 991 993 O
low 120 123 994 997 B-treatment
molecular 124 133 998 1007 I-treatment
weight 134 140 1008 1014 I-treatment
heparin 141 148 1015 1022 I-treatment

Investigational 0 15 1023 1038 B-treatment
therapy 16 23 1039 1046 I-treatment
or 24 26 1047 1049 O
non 27 30 1050 1053 B-treatment
cytotoxic 31 40 1054 1063 I-treatment
therapy 41 48 1064 1071 I-treatment
- 49 50 1072 1073 O
2 51 52 1074 1075 B-lower_bound
weeks 53 58 1076 1081 I-lower_bound

Karnofsky 0 9 1082 1091 B-clinical_variable
Performance 10 21 1092 1103 I-clinical_variable
status 22 28 1104 1110 I-clinical_variable
≥ 29 30 1111 1112 O
60 31 33 1113 1115 B-lower_bound
% 33 34 1115 1116 I-lower_bound

Known 0 5 1117 1122 O
dihydropyrimidine 6 23 1123 1140 B-chronic_disease
dehydrogenase 24 37 1141 1154 I-chronic_disease
deficiency 38 48 1155 1165 I-chronic_disease

Known 0 5 1166 1171 O
hypersensitivity 6 22 1172 1188 O
to 23 25 1189 1191 O
5 26 27 1192 1193 B-allergy_name
- 27 28 1193 1194 I-allergy_name
fluorouracil 28 40 1194 1206 I-allergy_name
, 40 41 1206 1207 O
capecitabine 42 54 1208 1220 B-allergy_name
, 54 55 1220 1221 O
bevacizumab 56 67 1222 1233 B-allergy_name
or 68 70 1234 1236 O
to 71 73 1237 1239 O
any 74 77 1240 1243 O
component 78 87 1244 1253 B-allergy_name
of 88 90 1254 1256 I-allergy_name
the 91 94 1257 1260 I-allergy_name
investigational 95 110 1261 1276 I-allergy_name
products 111 119 1277 1285 I-allergy_name
or 120 122 1286 1288 I-allergy_name
compounds 123 132 1289 1298 I-allergy_name
of 133 135 1299 1301 I-allergy_name
similar 136 143 1302 1309 I-allergy_name
chemical 144 152 1310 1318 I-allergy_name
composition 153 164 1319 1330 I-allergy_name

Men 0 3 1331 1334 B-gender
treated 4 11 1335 1342 O
or 12 14 1343 1345 O
enrolled 15 23 1346 1354 O
on 24 26 1355 1357 O
this 27 31 1358 1362 O
protocol 32 40 1363 1371 O
must 41 45 1372 1376 O
also 46 50 1377 1381 O
agree 51 56 1382 1387 O
to 57 59 1388 1390 O
use 60 63 1391 1394 O
adequate 64 72 1395 1403 O
contraception 73 86 1404 1417 O
prior 87 92 1418 1423 O
to 93 95 1424 1426 O
the 96 99 1427 1430 O
study 100 105 1431 1436 O
, 105 106 1436 1437 O
for 107 110 1438 1441 O
the 111 114 1442 1445 O
duration 115 123 1446 1454 O
of 124 126 1455 1457 O
study 127 132 1458 1463 O
participation 133 146 1464 1477 O
, 146 147 1477 1478 O
and 148 151 1479 1482 O
through 152 159 1483 1490 O
30 160 162 1491 1493 B-upper_bound
days 163 167 1494 1498 I-upper_bound
after 168 173 1499 1504 O
the 174 177 1505 1508 O
last 178 182 1509 1513 O
dose 183 187 1514 1518 O
of 188 190 1519 1521 O
study 191 196 1522 1527 O
drug 197 201 1528 1532 O

No 0 2 1533 1535 O
active 3 9 1536 1542 O
bleeding 10 18 1543 1551 O
or 19 21 1552 1554 O
pathological 22 34 1555 1567 B-chronic_disease
condition 35 44 1568 1577 I-chronic_disease
that 45 49 1578 1582 O
carries 50 57 1583 1590 O
a 58 59 1591 1592 O
high 60 64 1593 1597 O
risk 65 69 1598 1602 O
of 70 72 1603 1605 O
bleeding 73 81 1606 1614 O
( 82 83 1615 1616 O
e.g. 83 87 1616 1620 O
, 87 88 1620 1621 O
tumor 89 94 1622 1627 B-cancer
involving 95 104 1628 1637 O
major 105 110 1638 1643 O
vessels 111 118 1644 1651 O
or 119 121 1652 1654 O
known 122 127 1655 1660 O
varices 128 135 1661 1668 O
) 135 136 1668 1669 O

Patients 0 8 1670 1678 O
on 9 11 1679 1681 O
full 12 16 1682 1686 O
- 16 17 1686 1687 O
dose 17 21 1687 1691 O
anticoagulants 22 36 1692 1706 B-treatment

Platelet 0 8 1707 1715 B-clinical_variable
count 9 14 1716 1721 I-clinical_variable
≥ 15 16 1722 1723 O
100,000 17 24 1724 1731 B-lower_bound
/ 24 25 1731 1732 I-lower_bound
mcL 25 28 1732 1735 I-lower_bound

Pregnant 0 8 1736 1744 B-pregnancy

Prothrombin 0 11 1745 1756 B-clinical_variable
time 12 16 1757 1761 I-clinical_variable
/ 16 17 1761 1762 I-clinical_variable
international 17 30 1762 1775 I-clinical_variable
normalized 31 41 1776 1786 I-clinical_variable
ratio 42 47 1787 1792 I-clinical_variable
( 48 49 1793 1794 I-clinical_variable
PT 49 51 1794 1796 I-clinical_variable
/ 51 52 1796 1797 I-clinical_variable
INR 52 55 1797 1800 I-clinical_variable
) 55 56 1800 1801 I-clinical_variable
< 57 58 1802 1803 O
1.4 59 62 1804 1807 B-upper_bound
for 63 66 1808 1811 O
patients 67 75 1812 1820 O
not 76 79 1821 1824 O
on 80 82 1825 1827 O
warfarin 83 91 1828 1836 B-treatment

Should 0 6 1837 1843 O
a 7 8 1844 1845 O
woman 9 14 1846 1851 B-gender
become 15 21 1852 1858 O
pregnant 22 30 1859 1867 B-pregnancy
or 31 33 1868 1870 O
suspect 34 41 1871 1878 O
she 42 45 1879 1882 O
is 46 48 1883 1885 O
pregnant 49 57 1886 1894 O
while 58 63 1895 1900 O
participating 64 77 1901 1914 O
in 78 80 1915 1917 O
this 81 85 1918 1922 O
study 86 91 1923 1928 O
, 91 92 1928 1929 O
she 93 96 1930 1933 O
should 97 103 1934 1940 O
inform 104 110 1941 1947 O
her 111 114 1948 1951 O
treating 115 123 1952 1960 O
physician 124 133 1961 1970 O
immediately 134 145 1971 1982 O

Significant 0 11 1983 1994 O
chronic 12 19 1995 2002 O
gastrointestinal 20 36 2003 2019 B-chronic_disease
disorder 37 45 2020 2028 I-chronic_disease
with 46 50 2029 2033 O
diarrhea 51 59 2034 2042 O
as 60 62 2043 2045 O
a 63 64 2046 2047 O
major 65 70 2048 2053 O
symptom 71 78 2054 2061 O
( 79 80 2062 2063 O
e.g. 80 84 2063 2067 O
, 84 85 2067 2068 O
Crohn 86 91 2069 2074 B-chronic_disease
's 91 93 2074 2076 I-chronic_disease
disease 94 101 2077 2084 I-chronic_disease
, 101 102 2084 2085 O
malabsorption 103 116 2086 2099 B-chronic_disease
, 116 117 2099 2100 O
or 118 120 2101 2103 O
Grade 121 126 2104 2109 O
≥2 127 129 2110 2112 O
( 130 131 2113 2114 O
National 131 139 2114 2122 O
Cancer 140 146 2123 2129 O
Institute 147 156 2130 2139 O
[ 157 158 2140 2141 O
NCI 158 161 2141 2144 O
] 161 162 2144 2145 O
Common 163 169 2146 2152 O
Terminology 170 181 2153 2164 O
Criteria 182 190 2165 2173 O
for 191 194 2174 2177 O
Adverse 195 202 2178 2185 O
Events 203 209 2186 2192 O
Version 210 217 2193 2200 O
4.0 218 221 2201 2204 O
[ 222 223 2205 2206 O
CTCAE 223 228 2206 2211 O
v.4.0 229 234 2212 2217 O
] 234 235 2217 2218 O
diarrhea 236 244 2219 2227 O
of 245 247 2228 2230 O
any 248 251 2231 2234 O
etiology 252 260 2235 2243 O
at 261 263 2244 2246 O
screening 264 273 2247 2256 O
) 273 274 2256 2257 O

Systolic 0 8 2258 2266 B-clinical_variable
blood 9 14 2267 2272 I-clinical_variable
pressure 15 23 2273 2281 I-clinical_variable
≤ 24 25 2282 2283 O
160 26 29 2284 2287 B-upper_bound
mg 30 32 2288 2290 I-upper_bound
Hg 33 35 2291 2293 I-upper_bound
or 36 38 2294 2296 O
diastolic 39 48 2297 2306 B-clinical_variable
pressure 49 57 2307 2315 I-clinical_variable
≤ 58 59 2316 2317 O
90 60 62 2318 2320 B-upper_bound
mg 63 65 2321 2323 I-upper_bound
Hg 66 68 2324 2326 I-upper_bound
within 69 75 2327 2333 O
14 76 78 2334 2336 B-upper_bound
days 79 83 2337 2341 I-upper_bound
prior 84 89 2342 2347 I-upper_bound
to 90 92 2348 2350 O
study 93 98 2351 2356 O
registration 99 111 2357 2369 O

Total 0 5 2370 2375 B-clinical_variable
bilirubin 6 15 2376 2385 I-clinical_variable
< 16 17 2386 2387 O
1.5 18 21 2388 2391 B-upper_bound
x 22 23 2392 2393 I-upper_bound
institutional 24 37 2394 2407 B-clinical_variable
upper 38 43 2408 2413 I-clinical_variable
limit 44 49 2414 2419 I-clinical_variable
of 50 52 2420 2422 I-clinical_variable
normal 53 59 2423 2429 I-clinical_variable
( 60 61 2430 2431 I-clinical_variable
ULN 61 64 2431 2434 I-clinical_variable
) 64 65 2434 2435 I-clinical_variable

Urine 0 5 2436 2441 B-clinical_variable
protein 6 13 2442 2449 I-clinical_variable
screened 14 22 2450 2458 O
by 23 25 2459 2461 O
urine 26 31 2462 2467 O
analysis 32 40 2468 2476 O
for 41 44 2477 2480 O
urine 45 50 2481 2486 B-clinical_variable
protein 51 58 2487 2494 I-clinical_variable
creatinine 59 69 2495 2505 I-clinical_variable
( 70 71 2506 2507 I-clinical_variable
UPC 71 74 2507 2510 I-clinical_variable
) 74 75 2510 2511 I-clinical_variable
ratio 76 81 2512 2517 I-clinical_variable

Women 0 5 2518 2523 B-gender
of 6 8 2524 2526 O
childbearing 9 21 2527 2539 O
potential 22 31 2540 2549 O
and 32 35 2550 2553 O
men 36 39 2554 2557 O
must 40 44 2558 2562 O
agree 45 50 2563 2568 B-contraception_consent
to 51 53 2569 2571 I-contraception_consent
use 54 57 2572 2575 I-contraception_consent
adequate 58 66 2576 2584 I-contraception_consent
contraception 67 80 2585 2598 I-contraception_consent
( 81 82 2599 2600 O
hormonal 82 90 2600 2608 B-contraception_consent
or 91 93 2609 2611 I-contraception_consent
barrier 94 101 2612 2619 I-contraception_consent
method 102 108 2620 2626 I-contraception_consent
of 109 111 2627 2629 I-contraception_consent
birth 112 117 2630 2635 I-contraception_consent
control 118 125 2636 2643 I-contraception_consent
; 125 126 2643 2644 O
abstinence 127 137 2645 2655 B-contraception_consent
) 137 138 2655 2656 O
prior 139 144 2657 2662 O
to 145 147 2663 2665 O
study 148 153 2666 2671 O
entry 154 159 2672 2677 O
, 159 160 2677 2678 O
for 161 164 2679 2682 O
the 165 168 2683 2686 O
duration 169 177 2687 2695 O
of 178 180 2696 2698 O
study 181 186 2699 2704 O
participation 187 200 2705 2718 O
, 200 201 2718 2719 O
and 202 205 2720 2723 O
through 206 213 2724 2731 O
30 214 216 2732 2734 B-upper_bound
days 217 221 2735 2739 I-upper_bound
after 222 227 2740 2745 O
the 228 231 2746 2749 O
last 232 236 2750 2754 O
dose 237 241 2755 2759 O
of 242 244 2760 2762 O
study 245 250 2763 2768 O
drug 251 255 2769 2773 O

cytotoxic 0 9 2774 2783 B-treatment
chemotherapy 10 22 2784 2796 I-treatment

for 0 3 2797 2800 O
temozolomide 4 16 2801 2813 B-treatment
21 17 19 2814 2816 B-lower_bound
of 20 22 2817 2819 O
28 23 25 2820 2822 B-upper_bound
days 26 30 2823 2827 I-upper_bound
, 30 31 2827 2828 O
7 32 33 2829 2830 O
days 34 38 2831 2835 O
after 39 44 2836 2841 O
most 45 49 2842 2846 O
recent 50 56 2847 2853 O
dose 57 61 2854 2858 O
; 61 62 2858 2859 O
etoposide 63 72 2860 2869 B-treatment
14 73 75 2870 2872 B-lower_bound
of 76 78 2873 2875 O
21 79 81 2876 2878 B-upper_bound
days 82 86 2879 2883 I-upper_bound
, 86 87 2883 2884 O
7 88 89 2885 2886 O
days 90 94 2887 2891 O
after 95 100 2892 2897 O
last 101 105 2898 2902 O
dose 106 110 2903 2907 O

have 0 4 2908 2912 O
adequate 5 13 2913 2921 O
organ 14 19 2922 2927 O
function 20 28 2928 2936 O
and 29 32 2937 2940 O
laboratory 33 43 2941 2951 O
parameters 44 54 2952 2962 O
within 55 61 2963 2969 O
21 62 64 2970 2972 B-upper_bound
days 65 69 2973 2977 I-upper_bound
of 70 72 2978 2980 O
study 73 78 2981 2986 O
entry 79 84 2987 2992 O

have 0 4 2993 2997 O
histologically 5 19 2998 3012 O
or 20 22 3013 3015 O
cytologically 23 36 3016 3029 O
confirmed 37 46 3030 3039 O
WHO 47 50 3040 3043 O
grade 51 56 3044 3049 B-cancer
4 57 58 3050 3051 I-cancer
glioma 59 65 3052 3058 I-cancer
for 66 69 3059 3062 O
which 70 75 3063 3068 O
a 76 77 3069 3070 O
clinically 78 88 3071 3081 O
indicated 89 98 3082 3091 O
tumor 99 104 3092 3097 B-treatment
resection 105 114 3098 3107 I-treatment
is 115 117 3108 3110 O
planned 118 125 3111 3118 O

standard 0 8 3119 3127 O
intervals 9 18 3128 3137 O
depending 19 28 3138 3147 O
on 29 31 3148 3150 O
the 32 35 3151 3154 O
most 36 40 3155 3159 O
recent 41 47 3160 3166 O
regimen 48 55 3167 3174 O
. 55 56 3174 3175 O
i.e. 57 61 3176 3180 O
, 61 62 3180 3181 O
for 63 66 3182 3185 O
temozolomide 67 79 3186 3198 B-treatment
5 80 81 3199 3200 O
of 82 84 3201 3203 O
28 85 87 3204 3206 O
, 87 88 3206 3207 O
23 89 91 3208 3210 O
days 92 96 3211 3215 O
after 97 102 3216 3221 O
most 103 107 3222 3226 O
recent 108 114 3227 3233 O
temozolomide 115 127 3234 3246 O

surgery 0 7 3247 3254 B-treatment
- 8 9 3255 3256 O
4 10 11 3257 3258 B-upper_bound
weeks 12 17 3259 3264 I-upper_bound

